Skip to main content

Advertisement

SpringerLink
Log in

A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Brain metastases (BMs) are frequently occurred in lung adenocarcinoma with driver mutation. There is a need to explore multi-discipline treatments and prognostic factors in those patients with most frequent driver mutations: EGFR mutation and ALK fusion. In the retrospective study, different therapies and prognostic factors were compared between EGFR and ALK-driven lung adenocarcinoma with BMs. 516 patients with EGFR mutation and 76 with ALK fusion were screened for this study, 303 (58.7%) and 34 (44.7%) had BM respectively. In multivariate analyses, the pretreatment factors including delayed BMs and asymptomatic BMs, treatment strategies including the first-generation tyrosine kinase inhibitor (TKI) and cranial radiotherapy (RT) treatment, were associated with much better OS in EGFR mutation patients. Moreover, we found EGFR-mutation patients receiving erlotinib would achieve better survival than those receiving gefitinib (P = 0.032). However, BM patients with ALK fusion treated by only the first generation TKI (HR = 0.23, P = 0.036) or cranial RT (HR = 0.12, P = 0.003), had better OS. After balancing of baseline characteristics of the two groups, there was no significant difference in the survival between BM patients with EGFR mutation and ALK fusion. And only cranial RT was associated with better survival in those patients (HR = 0.52, P < 0.001). In the BM patients of lung adenocarcinoma with driver mutation, TKI underlie the therapy strategies, but cranial RT still plays an important role while receiving the first generation TKI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC, Shih JY (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naïve non-small-cell lung cancer. Ann Oncol 20(4):696–702

    Article  Google Scholar 

  2. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J (2006) Frequent EGFR mutations in BMs of lung adenocarcinoma. Int J Cancer 119:1491–1494

    Article  CAS  Google Scholar 

  3. Kang HJ, Lim HJ, Park JS, Cho YJ, Yoon HI, Chung JH, Lee JH, Lee CT (2014) Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med 108:388–394

    Article  Google Scholar 

  4. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and BMs. J Clin Oncol 33:1881–1888

    Article  CAS  Google Scholar 

  5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  CAS  Google Scholar 

  6. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247–4253

    Article  CAS  Google Scholar 

  7. Zhou JX, Yang H, Deng Q, Gu X, He P, Lin Y, Zhao M, Jiang J, Chen H, Lin Y, Yin W, Mo L, He J (2013) Oncogenic driver mutations in non-small cell lung cancer patients at various clinical stages. Ann Oncol 24:1319–1325

    Article  CAS  Google Scholar 

  8. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125

    Article  CAS  Google Scholar 

  9. Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS (2018) Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in east asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol 13:1539–1548

    Article  Google Scholar 

  10. Kawabe T, Phi JH, Yamamoto M, Kim DG, Barfod BE, Urakawa Y (2012) Treatment of brain metastasis from lung cancer. Prog Neurol Surg 25:148–155

    Article  Google Scholar 

  11. Eisenhauer EA, Therasse P, Bogaerts J, Schwarts LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  Google Scholar 

  12. Kashima J, Okuma Y, Miwa M, Hosomi Y (2016) Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors. Med Oncol 33:129

    Article  Google Scholar 

  13. Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A (2015) Brain metastases in NSCLC—are TKIs changing the treatment strategy? Anticancer Res 35:5797–5806

    CAS  PubMed  Google Scholar 

  14. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors 316 in three Radiation Therapy Oncology Group (RTOG) BMs trials. Int J Radiat Oncol Biol Phys 37:745–751

    Article  CAS  Google Scholar 

  15. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with BMs: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–514

    Article  Google Scholar 

  16. Lorenzoni J, Devriendt D, Massager N, David P, Ruíz S, Vanderlinden B, Van Houtte P, Brotchi J, Levivier M (2004) Radiosurgery for treatment of BMs: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 60:218–224

    Article  Google Scholar 

  17. Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, Huang YS, Yan HH, Ren S, Liu Y, Yang JJ (2013) Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic BMs: a phase II study (CTONG-0803). Ann Oncol 24:993–999

    Article  Google Scholar 

  18. Hochmair M (2018) Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from BMs and/or leptomeningeal disease. Target Oncol 13:269–285

    Article  Google Scholar 

  19. Ke SB, Qiu H, Chen JM, Shi W, Chen YS (2018) Therapeutic effect of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) Combined with whole brain RT on patients with EGFR mutation-positive lung adenocarcinoma and BMs. Curr Med Sci 38:1062–1068

    Article  CAS  Google Scholar 

  20. Sung S, Lee SW, Kwak YK, Kang JH, Hong SH, Kim YS (2018) Intracranial control and survival outcome of tyrosine inhibitor(TKI)alone versus TKI plus RT for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer. J Neurooncol 139:205–213

    Article  CAS  Google Scholar 

  21. Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L, Nexo E, Meldgaard P (2011) Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 6:1287–1289

    Article  Google Scholar 

  22. Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z (2007) Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57:359–364

    Article  Google Scholar 

  23. Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR (2018) Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol 29:2214–2222

    Article  CAS  Google Scholar 

  24. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34:123–129

    Article  CAS  Google Scholar 

  25. Martínez P, Mak RH, Oxnard GR (2017) Targeted therapy as an alternative to whole-brain RT in EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases. JAMA Oncol 3:1274–1275

    Article  Google Scholar 

  26. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL (2017) Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol 35:1070–1077

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Weidan Qu for the patients’ follow-up. The authors were responsible for all content and editorial decisions for our report.

Author information

Author notes

  1. Haihong Yang and Dongyun He have contributed equally to this work.

Authors and Affiliations

  1. Department of Thoracic Oncology, State Key Laboratory of Respiratory Diseases, National Clinical Research Center of Respiratory Disease, 151 Yanjiang Road, Guangzhou, 510120, China

    Haihong Yang, Dongyun He, Fengnan Wang & Zixian Xie

  2. The Center for Translational Medicine, The First Affiliated Hospital, Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, 510120, China

    Qiuhua Deng

Authors
  1. Haihong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dongyun He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fengnan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiuhua Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zixian Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haihong Yang.

Ethics declarations

Conflict of interest

Author Haihong Yang, Fengnan Wang, Qiuhua Deng, Yuan Qiu, Dongyun He declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, H., He, D., Wang, F. et al. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation. Clin Exp Metastasis 37, 391–399 (2020). https://doi.org/10.1007/s10585-020-10026-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-020-10026-2

Keywords

Search

Navigation